01:10 , Dec 7, 2016 |  BC Extra  |  Clinical News

GNS identifies disease drivers from CoMMpass data

GNS Healthcare Inc. (Cambridge, Mass.) said it has identified four genes as "top drivers" of high-risk multiple myeloma. Using its machine learning technology, the company is collaborating with the Multiple Myeloma Research Foundation (MMRF) to...
08:00 , Dec 14, 2015 |  BioCentury  |  Product Development

Following CoMMpass

Amidst a flood of promising data for hot targets, indications and technologies at this year's American Society of Hematology meeting, one collection of presentations stands out not only for the wide-reaching implications of their data,...
07:00 , Aug 4, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Cancer Cyclin dependent kinase 5 (CDK5) In vitro studies suggest inhibiting CDK5 could help prevent metastatic cancers. In cellular models of metastasis and in...
07:00 , Apr 18, 2011 |  BioCentury  |  Strategy

Supercharging Astex

SuperGen Inc. and Astex Therapeutics Ltd. are betting that by combining the former's cash with the latter's pipeline and drug discovery platform, they can create a mid-tier cancer company. SuperGen has plenty of cash from...
07:00 , Apr 11, 2011 |  BC Week In Review  |  Company News

Astex Therapeutics, SuperGen deal

SuperGen will acquire fellow cancer company Astex in a cash and stock deal. Astex shareholders will receive $25 million in cash, plus shares that will represent 35% of the combined company's outstanding shares after the...
00:30 , Apr 8, 2011 |  BC Extra  |  Company News

SuperGen to acquire Astex

SuperGen Inc. (NASDAQ:SUPG) will acquire fellow cancer company Astex Therapeutics Ltd. (Cambridge, U.K.) in a cash and stock deal. Astex shareholders will receive $25 million in cash, plus shares that will represent 35% of the...
07:00 , Aug 23, 2010 |  BC Week In Review  |  Clinical News

AT7519: Phase II started

Astex began an open-label, U.S. Phase II trial to evaluate intravenous AT7519 alone or with Velcade bortezomib in up to 30 patients. Millennium Pharmaceuticals Inc. , a subsidiary of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka,...
08:00 , Nov 16, 2009 |  BioCentury  |  Finance

Ebb & Flow

Although the terms of the acquisition of BioTrove Inc. by Life Technologies Corp. (NASDAQ:LIFE) haven't been undisclosed, the transaction could result in a more than 10X return over the next 12 months, according to investor...
07:00 , Apr 20, 2009 |  BC Week In Review  |  Clinical News

AT7519: Phase I data

In a dose-escalation, international Phase I trial in patients with refractory solid tumors, 3.6-34 mg/m 2/day of IV AT7519 inhibited CDK as assessed by a reduction in phospho- nucleophosmin and proliferating cell nuclear antigen (PCNA)...
08:00 , Dec 8, 2008 |  BC Week In Review  |  Clinical News

Astex Therapeutics preclinical data

In mice with MM, AT7519 significantly improved overall survival vs. control (40.0 vs. 27.5 days, p=0.0324). The cyclin dependent kinase (CDK) inhibitor also slowed tumor growth vs. control. Data will be presented at the American...